About Carisma Therapeutics
Carisma Therapeutics (NASDAQ:CARM) is a biotechnology company dedicated to the discovery and development of innovative therapies. With a focus on engineered macrophage-based treatments, Carisma is at the forefront of initiating groundbreaking approaches to combat cancer and other critical illnesses. The company's operations span from research and development in cell therapy platforms to advancing clinical studies aimed at unlocking new treatment pathways. By leveraging its unique CAR-Macrophage platform, Carisma aims to harness the power of the immune system, offering new hope for patients through targeted, immune-based therapies. The company's primary objective is to deliver transformative treatments that can significantly improve patient outcomes, steering the future of immunotherapy towards more effective and less invasive options.
Snapshot
Operations
Products and/or services of Carisma Therapeutics
- Development of chimeric antigen receptor macrophage (CAR-M) therapy targeting HER2 overexpressing tumors.
- Advancement of CAR-M therapies for solid tumors with a focus on safety and efficacy.
- Research into novel engineered macrophages for enhanced phagocytosis and anti-tumor activity.
- Collaborations with industry and academic partners to broaden the applicability of CAR-M technology across various cancer types.
- Investment in proprietary manufacturing processes to streamline the production of CAR-M cells.
- Engagement in preclinical studies to explore the potential of CAR-M therapies in treating other diseases beyond cancer.
Carisma Therapeutics executive team
- Dr. Saar Gill M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board
- Ms. Natalie McAndrewVice President of Finance